Kay Hagan actually said...

"Dodd-Frank represents a major step forward on this issue by granting important new authorities to our prudential regulators."

"I'm wondering if and how FDA can speed this up now?"

"I'm concerned that duplicative regulation could slow innovation, impeding improvements to patient care as well as the job growth."

"One complaint that I continue to hear from constituent companies is that the FDA's medical device review process is unpredictable and inconsistent."